An increasing number of studies on TCM treatment of myasthenia gravis have confirmed the clinical efficacy of various TCM and acupuncture intervention methods. However, most clinical trials of TCM on the treatment of myasthenia gravis patients receiving interventional therapy is limitedly accepted around the world in consideration of high risks of selective reporting bias or missing data and using no accepted outcomes. These defects hinder synthesizing the results in meta-analyses, which reduce the value of trials. Thus, the development of a core outcome set (COS) that should be measured in all clinical trials for a specific health condition has been recommended. So it is necessary to develop a COS for myasthenia gravis in clinical trials of TCM.
ContributorsJi Xinchen,Wang Baitong,Xu Peng,Zhang Dongmei,Li Qiaoying, Chang Tianying,Lu¨ Zhiguo, Wang Jian
Disease Category: Neurology
Disease Name: Myasthenia Gravis
Age Range: 18 - 100
Sex: Either
Nature of Intervention: Traditional Chinese Medicine
- Clinical experts
- Consumers (caregivers)
- Consumers (patients)
- Methodologists
- Patient/ support group representatives
- Researchers
- Service commissioners
- Service providers
- Service users
- Statisticians
- COS for clinical trials or clinical research
- COS for practice
- Consensus conference
- Delphi process
- Semi structured discussion
- Survey
- Systematic review
We have conducted a systematic review, a patient interview to develop an outcome list, and have conducted two rounds of the Delphi process. We will now conduct a consensus meeting to develop the core outcome set.